http://www.reportbuyer.com/rss.htmlIn this section you will find information products, including market research reports, on the following sector: Asthmaen-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/chinese_markets_asthma_treatment_drugs.htmlChina's demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. 47d8ea9929ed112f9f401bb8702f3bdcSat, 06 Jun 2009 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/china_asthma_drug_market_report.htmlAccording to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide. One out of every 250 disease-related deaths was caused by asthma. In China, the incidence rate of asthma patients has continuously increased in the recent years, especially among urban children. c1bf2f0501828ce6ce20bdc4f797e9b2Tue, 05 May 2009 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/interleukin_13_il_13_antibodies.htmlProduct description The present Brief Report about biologics such as antibodies, proteins, peptides, antisense and small interference RNA (siRNA) targeting the cytokine interleukin-13 or its receptors IL-13R alpha and IL-4Ralpha provides a competitor analysis of these anti-inflammatory molecules. R&D projects of IL-13 antagonists to treat asthma and other pulmonary or allergic diseases are discussed as of February 2008. At least six molecules are in early clinical development up to phase II. 15c824e13c9f45c09578364fd5db4a51Sat, 02 Feb 2008 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/gm_csf_antibodies.htmlProduct description The present Brief Report about molecules targeting granulocyte-macrophage colony-stimulating factor (GM-CSF) and its receptor or M-CSF or G-CSF and its receptor provides a competitor analysis of these anti-inflammatory antibodies. R&D projects of antibodies targeting GM-CSF/R, M-CSF or G-CSF/R to treat rheumatoid arthritis and other inflammatory diseases such as asthma, COPD, multiple sclerosis and psoriasis are discussed as of January 2008. A total of three different molecules are already in early clinical development and three others to follow within one year. 9a3b42ab7c7a63f69e4ce2037cbebd67Tue, 01 Jan 2008 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/commercial_insight_asthma_copd_combination_products_blockbuster_potential.html Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets. Indication based forecasts for asthma/COPD products and significant pipeline drugs Assessment of country-specific drivers and resistors likely to impact the market Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance Asthma/COPD sales in the seven major markets are expected to grow to over $24 billion annually by 2010 and drop slightly thereafter due to patent expiries of key products. a3c4a5f6c307423570c43abf7b0b6e34Wed, 11 Jul 2007 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/gsks_cervarix.htmlPlease Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order,the client will receive an email with information on accessing their purchase. 13cc527c337e3d72aa775fcb11c01907Thu, 22 Mar 2007 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/prostate_breast_cancer.htmlIntroduction The treatment for breast and prostate cancer are under intense progress. Cancer of the prostate is the second most frequently diagnosed cancer in men in the US and approximately 3 million women in the US are living with breast cancer. Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. 11a0684257231cd1ccbed873c9552650Sat, 03 Mar 2007 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/global_pipeline_review_analysis_hematological_malignancies.htmlIntroduction The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. 375ea8ad99369549eeeed201d3a977fbSat, 03 Mar 2007 12:00:00 GBDiseases/Asthmahttp://www.reportbuyer.com/pharma_healthcare/diseases/asthma/immunotherapy_cancer.htmlCancer immunotherapeutics, in particular monoclonal antibody-based products and vaccines, are transforming the cancer treatment market and providing a whole new arsenal of weapons. The introduction of the first monoclonal antibody product to the worldwide market for the treatment of cancer in 1998 initiated a cascade of additional monoclonal antibody products for the treatment of cancer that continues unabated. Average annual growth of monoclonal antibody products has stayed in the double digits since the late 1990s. b8a94a9730e4889c1901b283dcc6f460Wed, 03 Jan 2007 12:00:00 GBDiseases/Asthma